Table 1.
Baseline characteristics at screening for CAR-T infused patients.
| CAR-T Infused Patients Cohort (N = 145) | |
|---|---|
| Median age (min–max) | 60 years (21–84) |
| Female, n (%) | 50 (34%) |
| Histological subtype, n (%) | |
| DLBCL | 73 (50%) |
| HGBCL (NOS/DH/TH) | 20 (14%) |
| PMBCL | 4 (3%) |
| tFL | 48 (33%) |
| IPI score, n (%) | |
| Low | 28 (19%) |
| Low-intermediate | 49 (34%) |
| High-intermediate | 41 (28%) |
| High | 13 (9%) |
| Incompletely assessed, n (%) | 14 (10%) |
| Stage III–IV, n (%) | 124 (86%) |
| Bulky disease (nodal ≥ 10 cm and/or extranodal ≥ 5 cm), n (%) | 50 (34%) |
| Missing | 2 (1%) |
| Extranodal sites present, n (%) | 98 (68%) |
| 2 Sites | 26 (18%) |
| ≥3 Sites | 16 (11%) |
| Unknown number of sites | 2 (1%) |
| ECOG performance status, n (%) | |
| 0 | 85 (59%) |
| 1 | 49 (34%) |
| ≥2 | 11 (8%) |
| Primary refractory a, n (%) | 88 (61%) |
| Disease status, n (%) | |
| Relapse after last therapy line | 29 (20%) |
| Refractory to last therapy line | 116 (80%) |
| Prior therapy lines, median (min–max) | 2 (2–6) |
| ≥3 | 38 (26%) |
| Prior transplant, n (%) | |
| Autologous SCT | 42 (29%) |
| Allogeneic SCT | 3 (2%) |
| LDH, n (%) | |
| >1x ULN–2x ULN | 54 (37%) |
| ≥2x ULN | 22 (15%) |
| Missing | 12 (8%) |
| Hemoglobin < 6 mmol/L, n (%) | 44 (30%) |
| Missing | 2 (1%) |
| Ferritin > 1000 µg/L, n (%) | 20 (14%) |
| Missing | 82 (57%) |
| CRP > 50 mg/L, n (%) | 28 (19%) |
| Missing | 43 (30%) |
| Platelets < 75 × 109/L, n (%) | 17 (12%) |
| Missing | 3 (2%) |
| Neutrophil count < 0.5 × 109/L, n (%) | 7 (5%) |
| Missing | 30 (21%) |
| Lymphocyte count < 0.5 × 109/L, n (%) | 27 (19%) |
| Missing | 40 (28%) |
a Primary refractory was defined as no complete response to first-line treatment. Abbreviations: DLBCL: diffuse large B-cell lymphoma, ECOG: Eastern Cooperative Oncology Group, HGBCL: high-grade B-cell lymphoma, IPI: international prognostic index, PMBCL: primary mediastinal large B-cell lymphoma, SCT: stem cell transplantation, tFL: transformed follicular lymphoma.